Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4320
- Registration Number
- NCT05153135
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Managed Access Programs for LEE011, Ribociclib
- Conditions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05038631
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04964934
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT04862663
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 21
- Registration Number
- NCT04657679
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Emory University
- Registration Number
- NCT04585724
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT04417621
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.